Larissa Bergin's practice addresses the antitrust concerns arising from M&A matters, joint ventures, federal investigations, and commercial practices. She has overseen the antitrust aspects of corporate M&A, including due diligence, risk-shift negotiations, Hart-Scott-Rodino (HSR) filings, Second Requests, investigational hearings, integration planning, and consent decrees with federal agencies. She works with clients in a variety of industries, including the technology, health care, retail, and pharmaceutical sectors. Many of Larissa's clients have international reach, and she has been involved in matters that require advocacy before governments throughout Asia, the EU, and North America.
Larissa also advises clients on corporate contracting and operational practices that can run afoul of the antitrust laws, including supplier agreements, information sharing, competitive benchmarking, and Robinson-Patman Act pricing matters.
At the start of her career, Larissa clerked at the U.S. Court of Federal Claims, where she addressed intellectual property, tax, and government contract issues, including Serco, Inc. v. United States (also referred to as the Alliant protest), a bid-protest case involving a $50 billion procurement for government-wide information technology and services.
Larissa is a member of the Antitrust Section of the American Bar Association and is chair of the Food, Drug and Cosmetics Law Section of the New York State Bar Association. She is admitted in the New York, Connecticut, and District of Columbia bars.
Larissa has been quoted on MSNBC regarding how Obamacare has affected M&A activity and in Getting the Deal Through on generic drug approval.
Experience
Speaking Engagements
- January 2023
FTC's Proposed Rule Banning Noncompetes MCLE - January 2023
FDA Commissioner Califf's First Year - Initial Focus Areas and What to Expect in 2023 New York State Bar Association Annual Meeting - January 2021
Keynote Address with Acting Chief of Staff of the FDA, Julia Tierney, New York State Bar Association, Annual Meeting - March 2020
FTC Enforcement Authority: Recent Challenges, American Bar Association - January 2019
Blockchain in Healthcare, New York State Bar Association Annual Meeting - October 2018
Beyond the Basics of Blockchain: Current and Future Use Cases and Corresponding Regulatory Development, New York State Bar Association - January 2018
M&A Antitrust Risk Shifting Between Parties, Moderator, ABA Section of Antitrust Law - January 2018
Developments in Drug Law, New York State Bar Association Annual Meeting - May 2017
Broadcasting to a Different Audience: Interagency Review in Telecomm Mergers, moderator, ABA Section of Antitrust Law - January 2017
Developments in Drug Law, New York State Bar Association Annual Meeting - December 2016
Biosimilar Regulatory Compliance, Food and Drug Law Institute, Enforcement, Litigation, and Compliance Conference, Roundtable Discussion
- The Catholic University of America (J.D. magna cum laude 2007; Associate Editor, Law Review; Willem C. Vis International Commercial Arbitration Moot Team); Boston University (B.A. in Psychology and Sociology magna cum laude 2004)
- District of Columbia, New York, and Connecticut
- Legal intern, Federal Communications Commission, Media Bureau, Policy Division (2005-2006)
Chair of the Food, Drug and Cosmetic Law Section of the New York State Bar Association, which is at the forefront of addressing the current regulatory framework in light of new technologies and advancements, such as biologics
- Law Clerk to the Honorable Francis M. Allegra, U.S. Court of Federal Claims (2007-2008) and externship with the Honorable Jacob P. Hart, U.S. District Court, Eastern District of Pennsylvania (Summer 2005)